Tokyo Tape
Sign in
← Medinet

Annual report

2370.TEDINET S100UX6K
Period2023-10-01 → 2024-09-30
Filed2024-12-18
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 83
MetricValuePeriodScopeSource row
Revenue¥769m2023-10-01 → 2024-09-30StandaloneNet sales
Revenue¥662m2022-10-01 → 2023-09-30StandaloneNet sales
Revenue¥634m2021-10-01 → 2022-09-30dStandaloneNet sales (5-year summary)
Revenue¥683m2020-10-01 → 2021-09-30dStandaloneNet sales (5-year summary)
Revenue¥783m2019-10-01 → 2020-09-30dStandaloneNet sales (5-year summary)
Operating income−¥1.4bn2023-10-01 → 2024-09-30StandaloneOperating income
Operating income−¥1.4bn2022-10-01 → 2023-09-30StandaloneOperating income
Ordinary income−¥1.3bn2023-10-01 → 2024-09-30StandaloneOrdinary income
Ordinary income−¥1.4bn2022-10-01 → 2023-09-30StandaloneOrdinary income
Ordinary income−¥1.3bn2021-10-01 → 2022-09-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥871m2020-10-01 → 2021-09-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥837m2019-10-01 → 2020-09-30dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.3bn2023-10-01 → 2024-09-30StandaloneIncome before income taxes
Profit before tax−¥1.4bn2022-10-01 → 2023-09-30StandaloneIncome before income taxes
Net income−¥1.3bn2023-10-01 → 2024-09-30StandaloneProfit loss
Net income−¥1.4bn2022-10-01 → 2023-09-30StandaloneProfit loss
Net income−¥1.3bn2021-10-01 → 2022-09-30dStandaloneNet income loss (5-year summary)
Net income−¥843m2020-10-01 → 2021-09-30dStandaloneNet income loss (5-year summary)
Net income−¥842m2019-10-01 → 2020-09-30dStandaloneNet income loss (5-year summary)
Total assets¥5.7bnat 2024-09-30StandaloneAssets
Total assets¥5.6bnat 2023-09-30StandaloneAssets
Total assets¥6.1bnat 2022-09-30dStandaloneTotal assets (5-year summary)
Total assets¥5.4bnat 2021-09-30dStandaloneTotal assets (5-year summary)
Total assets¥5.2bnat 2020-09-30dStandaloneTotal assets (5-year summary)
Total liabilities¥509mat 2024-09-30StandaloneLiabilities
Total liabilities¥590mat 2023-09-30StandaloneLiabilities
Net assets / equity¥5.2bnat 2024-09-30StandaloneNet assets
Net assets / equity¥5.0bnat 2023-09-30StandaloneNet assets
Net assets / equity¥5.5bnat 2022-09-30dStandaloneNet assets
Net assets / equity¥4.9bnat 2021-09-30dStandaloneNet assets (5-year summary)
Net assets / equity¥4.8bnat 2020-09-30dStandaloneNet assets (5-year summary)
Cash and deposits¥4.7bnat 2024-09-30StandaloneCash and deposits
Cash and deposits¥4.4bnat 2023-09-30StandaloneCash and deposits
Cash & equivalents¥4.7bnat 2024-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.4bnat 2023-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.5bnat 2022-09-30dStandaloneCash and cash equivalents
Cash & equivalents¥4.1bnat 2021-09-30dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥3.6bnat 2020-09-30dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.3bn2023-10-01 → 2024-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.3bn2022-10-01 → 2023-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2021-10-01 → 2022-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥975m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥633m2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥65m2023-10-01 → 2024-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow¥3m2022-10-01 → 2023-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow−¥20m2021-10-01 → 2022-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥344m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥86m2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.5bn2023-10-01 → 2024-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.2bn2022-10-01 → 2023-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.6bn2021-10-01 → 2022-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.8bn2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-5.042023-10-01 → 2024-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.652022-10-01 → 2023-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.332021-10-01 → 2022-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-4.882020-10-01 → 2021-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.192019-10-01 → 2020-09-30dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥19.62at 2024-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥21.64at 2023-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥26.03at 2022-09-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥27.31at 2021-09-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥29.6at 2020-09-30dStandaloneNet assets per share (5-year summary)
Equity ratio91.1%at 2024-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.2%at 2023-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio90.7%at 2022-09-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio90.8%at 2021-09-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio90.7%at 2020-09-30dStandaloneEquity to asset ratio (5-year summary)
ROE-25.0%2023-10-01 → 2024-09-30StandaloneRate of return on equity (5-year summary)
ROE-27.3%2022-10-01 → 2023-09-30StandaloneRate of return on equity (5-year summary)
ROE-24.1%2021-10-01 → 2022-09-30dStandaloneRate of return on equity (5-year summary)
ROE-17.5%2020-10-01 → 2021-09-30dStandaloneRate of return on equity (5-year summary)
ROE-23.0%2019-10-01 → 2020-09-30dStandaloneRate of return on equity (5-year summary)
Shares issued264,515,306at 2024-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued232,160,757at 2023-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued211,730,423at 2022-09-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued178,750,423at 2021-09-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued160,830,423at 2020-09-30dStandaloneTotal number of issued shares (5-year summary)
Employees112at 2024-09-30StandaloneNumber of employees
Employees98at 2023-09-30StandaloneNumber of employees
Employees96at 2022-09-30dStandaloneNumber of employees
Employees83at 2021-09-30dStandaloneNumber of employees
Employees78at 2020-09-30dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2023-10-01 → 2024-09-30¥2m
Reconciling Itemsreconcilingdepreciation2023-10-01 → 2024-09-30¥18m
Reconciling Itemsreconcilingsegment assetsat 2024-09-30¥4.9bn
Reconciling Itemsreconcilingsegment profit2023-10-01 → 2024-09-30−¥577m
Cellular And Tissue Based Product Businessreportable segmentcapex2023-10-01 → 2024-09-30¥21m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2023-10-01 → 2024-09-30¥36m
Cellular And Tissue Based Product Businessreportable segmentemployeesat 2024-09-3018 pure
Cellular And Tissue Based Product Businessreportable segmentrevenue2023-10-01 → 2024-09-30¥245,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2023-10-01 → 2024-09-30¥245,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2024-09-30¥116m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2023-10-01 → 2024-09-30−¥435m
Contracted Cell Manufacturing Businessreportable segmentcapex2023-10-01 → 2024-09-30¥23m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2023-10-01 → 2024-09-30¥61m
Contracted Cell Manufacturing Businessreportable segmentemployeesat 2024-09-3078 pure
Contracted Cell Manufacturing Businessreportable segmentrevenue2023-10-01 → 2024-09-30¥768m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2023-10-01 → 2024-09-30¥768m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2024-09-30¥667m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2023-10-01 → 2024-09-30−¥374m
—segment totalcapex2023-10-01 → 2024-09-30¥44m
—segment totaldepreciation2023-10-01 → 2024-09-30¥97m
—segment totalrevenue2023-10-01 → 2024-09-30¥769m
—segment totalrevenue external2023-10-01 → 2024-09-30¥769m
—segment totalsegment assetsat 2024-09-30¥783m
—segment totalsegment profit2023-10-01 → 2024-09-30−¥808m
Reconciling Itemsreconcilingcapex2022-10-01 → 2023-09-30¥6m
Reconciling Itemsreconcilingdepreciation2022-10-01 → 2023-09-30¥19m
Reconciling Itemsreconcilingsegment assetsat 2023-09-30¥4.8bn
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2023-09-30−¥583m
Cellular And Tissue Based Product Businessreportable segmentcapex2022-10-01 → 2023-09-30¥25m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2022-10-01 → 2023-09-30¥28m
Cellular And Tissue Based Product Businessreportable segmentrevenue2022-10-01 → 2023-09-30¥467,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2022-10-01 → 2023-09-30¥467,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2023-09-30¥169m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2022-10-01 → 2023-09-30−¥496m
Contracted Cell Manufacturing Businessreportable segmentcapex2022-10-01 → 2023-09-30¥30m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2022-10-01 → 2023-09-30¥55m
Contracted Cell Manufacturing Businessreportable segmentrevenue2022-10-01 → 2023-09-30¥661m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2022-10-01 → 2023-09-30¥661m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2023-09-30¥668m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2022-10-01 → 2023-09-30−¥346m
—segment totalcapex2022-10-01 → 2023-09-30¥55m
—segment totaldepreciation2022-10-01 → 2023-09-30¥84m
—segment totalrevenue2022-10-01 → 2023-09-30¥662m
—segment totalrevenue external2022-10-01 → 2023-09-30¥662m
—segment totalsegment assetsat 2023-09-30¥837m
—segment totalsegment profit2022-10-01 → 2023-09-30−¥842m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 982
ItemContextValueUnit
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember103170000JPY
Increase in property plant and equipment and intangible assetsPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember29869000JPY
Increase in property plant and equipment and intangible assetsPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember24889000JPY
Increase in property plant and equipment and intangible assetsPrior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember54758000JPY
Increase in property plant and equipment and intangible assetsPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember6016000JPY
Increase in property plant and equipment and intangible assetsPrior1YearDuration_NonConsolidatedMember60775000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember768255000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember245000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember768501000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember768501000JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember768255000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember245000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember768501000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember768501000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember-373567000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember-434693000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember-808261000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember-576529000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember-1384790000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember667344000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember115550000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember782895000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_ReconcilingItemsMember4917135000JPY
AssetsCurrentYearInstant_NonConsolidatedMember5700031000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember60972000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember35985000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember96957000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember17694000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember114651000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember23014000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember20997000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember44011000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember2434000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember46446000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-12-18
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第29期（自　2023年10月１日　至　2024年９月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社メディネット
Company name in english cover pageFilingDateInstantMEDINET Co., Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　久布白　兼直
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都品川区勝島一丁目５番21号（同所は登記上の本店所在地であり、実際の業務は「最寄りの連絡場所」で行っております。）

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2023-09-30pass rounding
balance sheet identitynon_consolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-09-30pass
statement vs summary · net assetsnon_consolidated 2023-09-30pass
statement vs summary · net assetsnon_consolidated 2024-09-30pass
statement vs summary · operating cash flownon_consolidated 2022-10-01/2023-09-30pass
statement vs summary · operating cash flownon_consolidated 2023-10-01/2024-09-30pass
statement vs summary · revenuenon_consolidated 2022-10-01/2023-09-30pass
statement vs summary · revenuenon_consolidated 2023-10-01/2024-09-30pass
statement vs summary · total assetsnon_consolidated 2023-09-30pass
statement vs summary · total assetsnon_consolidated 2024-09-30pass